Recommended Topic Related To:


"Nov. 13, 2012 -- Women who get migraines are more likely than those who don't to develop small areas of tissue changes in their brains, a new study shows. At the same time, these changes do not seem to affect the women's thinking or memory.





Patients (N = 269) have received single injections of 8 to 12 mg sumatriptan without significant adverse effects. Volunteers (N = 47) have received single subcutaneous doses of up to 16 mg without serious adverse events.

No gross overdoses in clinical practice have been reported. The half-life of elimination of sumatriptan is about 2 hours [see CLINICAL PHARMACOLOGY], and therefore monitoring of patients after overdose with subcutaneous sumatriptan should continue while symptoms or signs persist, and for at least 10 hours. It is unknown what effect hemodialysis or peritoneal dialysis has on the serum concentrations of sumatriptan.


Intravenous Administration

ALSUMA is not designed to administer sumatriptan intravenously. Do not administer intravenously since sumatriptan may cause coronary vasospasm.

Ischemic or Vasospastic Coronary Artery Disease

Do not use ALSUMA in patients with ischemic heart disease (e.g. angina pectoris, history of myocardial infarction, or documented silent ischemia), or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's variant angina or other significant underlying cardiovascular disease. [see WARNINGS AND PRECAUTIONS]

Cerebrovascular Syndromes

Do not use ALSUMA in patients with cerebrovascular syndromes including (but not limited to) strokes of any type as well as transient ischemic attacks. [see WARNINGS AND PRECAUTIONS]

Peripheral Vascular Disease

Do not use ALSUMA in patients with peripheral vascular disease including (but not limited to) ischemic bowel disease. [see WARNINGS AND PRECAUTIONS]

Uncontrolled Hypertension

Because ALSUMA may increase blood pressure, do not use in patients with uncontrolled hypertension. [see WARNINGS AND PRECAUTIONS]

Ergotamine-Containing or Ergot-Type Medications or Other 5-HT1 Agonists (e.g. Triptans)

Do not use ALSUMA and any ergotamine-containing or ergot-type medication (such as dihydroergotamine or methysergide) within 24 hours of each other; do not use ALSUMA and another 5-HT1 agonist (e.g.triptan) within 24 hours of each other. [see DRUG INTERACTIONS]

The maximum recommended dose that may be given in 24 hours is two doses of ALSUMA separated by at least 1 hour. [see DOSAGE AND ADMINISTRATION]

Hemiplegic or Basilar Migraine

Do not use ALSUMA in patients with hemiplegic or basilar migraine.


ALSUMA is contraindicated in patients with known hypersensitivity to sumatriptan or any of its components.

Last reviewed on RxList: 4/26/2013
This monograph has been modified to include the generic and brand name in many instances.


Alsuma - User Reviews

Alsuma User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Alsuma sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Living Better

Find the secrets to longer life.

Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations